TipRanks
Advertisement
Advertisement

KAPA Stock Latest News

Kairos Pharma Reports Strong Interim Results for ENV-105 Combo
Company AnnouncementsKairos Pharma Reports Strong Interim Results for ENV-105 Combo
6d ago
8K
KAPA
Kairos Pharma announces interim efficacy data from Phase 2 trial of ENV-105
PremiumThe Fly
Kairos Pharma announces interim efficacy data from Phase 2 trial of ENV-105
6d ago
KAPA
Kairos Pharma Highlights Clinical Strategy in Investor Presentation
PremiumCompany Announcements
Kairos Pharma Highlights Clinical Strategy in Investor Presentation
28d ago
8K
KAPA
Kairos Pharma Announces 1-for-7 Reverse Stock Split
PremiumCompany Announcements
Kairos Pharma Announces 1-for-7 Reverse Stock Split
2M ago
8K
KAPA
Kairos Pharma announces 1-for-7 reverse stock split
PremiumThe Fly
Kairos Pharma announces 1-for-7 reverse stock split
2M ago
KAPA
Kairos Pharma Warns NYSE American Compliance Risks Could Trigger Delisting and Damage Investor Confidence
PremiumCompany AnnouncementsKairos Pharma Warns NYSE American Compliance Risks Could Trigger Delisting and Damage Investor Confidence
2M ago
KAPA
Pantginis Reiterates Buy on ENV-105’s Emerging Resistance-Reversal Profile and Bayer Collaboration; Price Target Maintained at $12
Premium
Ratings
Pantginis Reiterates Buy on ENV-105’s Emerging Resistance-Reversal Profile and Bayer Collaboration; Price Target Maintained at $12
3M ago
KAPA
Kairos Pharma, Bayer partner on prostate cancer therapy
Premium
Company Announcements
Kairos Pharma, Bayer partner on prostate cancer therapy
3M ago
8K
KAPA
Kairos Pharma announces collaboration with Bayer to enhance XOFIGO
PremiumThe Fly
Kairos Pharma announces collaboration with Bayer to enhance XOFIGO
3M ago
KAPA
Kairos Pharma announces interim safety data from Phase 1 trial of ENV-105
PremiumThe Fly
Kairos Pharma announces interim safety data from Phase 1 trial of ENV-105
3M ago
KAPA
Kairos Pharma Shareholders Approve Reverse Split, Governance Measures
PremiumCompany Announcements
Kairos Pharma Shareholders Approve Reverse Split, Governance Measures
3M ago
8K
KAPA
Kairos Pharma outlines mid-year oncology pipeline and funding plans
PremiumCompany Announcements
Kairos Pharma outlines mid-year oncology pipeline and funding plans
4M ago
8K
KAPA
Kairos Pharma issues letter from CEO that recaps year, details plans for 2026
PremiumThe FlyKairos Pharma issues letter from CEO that recaps year, details plans for 2026
4M ago
KAPA
Kairos Pharma Highlights Clinical Programs at LD Micro
Premium
Company Announcements
Kairos Pharma Highlights Clinical Programs at LD Micro
5M ago
8K
KAPA
Expanding Lung Cancer Franchise and Strategic Asset Acquisition Support Buy Rating on Kairos Pharma
Premium
Ratings
Expanding Lung Cancer Franchise and Strategic Asset Acquisition Support Buy Rating on Kairos Pharma
7M ago
KAPA
Kairos Pharma Acquires Rights to AI-Discovered EGFR Therapy
PremiumCompany Announcements
Kairos Pharma Acquires Rights to AI-Discovered EGFR Therapy
7M ago
8K
KAPA
Kairos Pharma to acquire CL-273 from Celyn Therapeutics
PremiumThe Fly
Kairos Pharma to acquire CL-273 from Celyn Therapeutics
7M ago
KAPA
Kairos Pharma to acquire to two clinical-stage oncology assets from Celyn
PremiumThe Fly
Kairos Pharma to acquire to two clinical-stage oncology assets from Celyn
8M ago
KAPA
Kairos Pharma Expands Lung Cancer Pipeline With Celyn Deal
PremiumCompany Announcements
Kairos Pharma Expands Lung Cancer Pipeline With Celyn Deal
8M ago
8K
KAPA
Kairos Pharma files $75M mixed securities shelf
PremiumThe FlyKairos Pharma files $75M mixed securities shelf
9M ago
KAPA
Kairos Pharma’s Promising Clinical Developments and Strategic Focus Drive Buy Rating
Premium
Ratings
Kairos Pharma’s Promising Clinical Developments and Strategic Focus Drive Buy Rating
11M ago
KAPA
Kairos Pharma Approves RSUs and Cash Bonuses
Premium
Company Announcements
Kairos Pharma Approves RSUs and Cash Bonuses
12M ago
8K
KAPA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >